Rekombinanter TNFRSF10B (Drozitumab Biosimilar) Antikörper

Produktnummer ABIN7795105

Der Maus Monoklonal anti-TNFRSF10B (Drozitumab Biosimilar) Antikörper (ABIN7795105) detektiert spezifisch TNFRSF10B (Drozitumab Biosimilar) in FACS und in vivo. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für Rekombinanter TNFRSF10B (Drozitumab Biosimilar) Antikörper (ABIN7795105)

Target: TNFRSF10B (Drozitumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TNFRSF10B (Drozitumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-TNFRSF10B (Drozitumab Biosimilar) Antikörper

Expressionssystem: Mammalian cells

Verwendungszweck: Drozitumab Biosimilar, TRAIL Monoclonal Antibody

Produktmerkmale: Drozitumab Biosimilar uses the same protein sequences as the therapeutic antibody drozitumab. Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells. Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human TRAIL

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Details zu TNFRSF10B (Drozitumab Biosimilar)

Target: TNFRSF10B (Drozitumab Biosimilar)

Andere Bezeichnung: Drozitumab Biosimilar

Substanzklasse: Biosimilar